Format

Send to

Choose Destination
Blood. 2011 Feb 10;117(6):2009-11. doi: 10.1182/blood-2010-07-295105. Epub 2010 Oct 20.

Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor?

Author information

1
Hematology Laboratory, University Hospital, and Inserm U892, Nantes, France. havetloiseau@chu-nantes.fr

Abstract

Many trials in myeloma are stratified on cytogenetic abnormalities. Among them, the most commonly chosen are the t(4;14), the del(17p), and the t(14;16). If data are well established for t(4;14) and del(17p), very few data support the use of t(14;16). To address this issue, we retrospectively analyzed 1003 patients with newly diagnosed myeloma for this abnormality. We identified 32 patients with the t(14;16). Compared with patients lacking the t(14;16), we did not observe any difference in overall survival (P = .28). Moreover, in multivariate analyses, the t(14;16) was not prognostic (P = .39). In conclusion, our data do not support the use of t(14;16)-specific probes in the diagnostic panels of multiple myeloma.

PMID:
20962323
DOI:
10.1182/blood-2010-07-295105
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center